Vendor Intelligence Report: Qingdao Sigma Chemical QSC

Published 13 Jun 2026. 26-page investigative report on who is behind Qingdao Sigma Chemical QSC: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 30 Finnrick lab tests, QSC’s record is 21 pass / 9 fail, an overall pass rate of 70%. The useful signal is product-specific, not vendor-wide: Tirzepatide is the more defensible tested GLP-1, while Retatrutide is materially weaker and loses buyer confidence under stricter grading. This narrow catalog still changes the purchase decision.

The identity picture is more complicated than a fake-site warning. Chinese registry records anchor QSC to an older Qingdao chemical-wholesale entity, but the Western-facing storefront cluster is new in 2026. A high-subscriber Telegram channel and the website channel give mutually exclusive ordering instructions, leaving buyers with an authentication problem before product quality is considered.

The legal and operational risk profile is unusually exposed. The report ties the late-2024 disruption to an operator-described enforcement action around steroid sales, then documents continued catalog overlap with controlled substances, crypto-only checkout, and customs declarations that do not match the apparent gray-market products. Those factors affect seizure risk, order continuity, and recovery leverage.

QSC’s reputation record adds a separate buyer-safety concern: MESO-Rx records document a permanent ban for doxxing a complaining customer, while seller-controlled reviews present a uniformly positive surface. The full dossier separates verified artifacts from forum allegations and shows where QSC may be comparatively supportable, where it is not, and how to verify channels before sending funds.

Inside the full report:

  • Complete Finnrick product-by-methodology breakdown, rating trajectories, and methodology-divergence charts for both tested products
  • Cnverify corporate registry exhibit and address cross-check across registry, website, and customs records
  • Domain-authentication analysis of qscpeptide.com, qsc-usa.com, qscpeptidelab.com, Telegram, and lookalike domains
  • Chronology of the 2024 enforcement action, shutdown reports, remediation claims, and 2026 storefront rollout
  • Controlled-substance catalog evidence and customs-declaration records, including MONOLAURIN and Honeysuckle Oil labeling
  • MESO-Rx doxxing exhibit, dispute-record review, and seller-controlled review comparison

Risk assessment

  • Retatrutide product-quality inconsistency — high: Retatrutide is the weak Finnrick product: 14 tests, 8 pass / 6 fail, 67.63% rating; buyers needing Retatrutide should prefer a stronger-testing vendor.
  • Tirzepatide residual quality-control risk — medium: Tirzepatide is QSC’s stronger product but still has 16 tests, 13 pass / 3 fail, 81.52% rating; verify batch-specific COA and consider independent testing.
  • Brand-authenticity and copycat risk — high: Telegram says QSC has no websites while qscpeptide.com/qsc-usa.com claim website-only ordering; lookalike domains including qingdaosigmachemical.com/.net are documented.
  • Controlled-substance and law-enforcement continuity risk — high: QSC listings include Testosterone Cypionate, Oxandrolone/Anavar, Dianabol, Halotestin and Modafinil; operator tied the 2024 raid to steroid sales.
  • Customs-deception and buyer seizure risk — high: Records show a MONOLAURIN customs declaration and operator admission of Honeysuckle Oil labeling; interception risk is shifted to buyers.
  • Customer-retaliation and dispute-handling risk — high: MESO-Rx records document a permanent ban for doxxing a complaining customer; 2025–2026 disputes include a reported 7.5k USD loss.
  • COA and batch-traceability risk — medium: Forum records report 2024-dated COAs used for 2025 product and QSC’s COA portal is new; unlabeled/no-batch vials limit traceability.
  • Payment recovery and unfulfilled-order risk — medium: qscpeptide.com uses crypto-only BTC/USDT payment via Blockonomics; pre-raid and 2026 complaint records show limited recovery leverage.
  • Review-curation / astroturfing risk — medium: qscpeptide.com shows 142 anonymized 5-star reviews while MESO-Rx, Trustpilot and Reddit contain negative dispute records.
  • Affiliate-promotion disclosure risk — medium: Two Reddit accounts circulated the same Peppys invite code without clear disclosure; scan found no X/coupon-site QSC codes, so exposure is narrow but material.